View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Boston Scientific Corp: 1 director

A director at Boston Scientific Corp sold/sold after exercising options 14,010 shares at 89.269USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dire...

Boston Scientific Corporation: Update to credit analysis following out...

Our credit view of this issuer reflects its leading position in key markets and its broad product and geographic diversification, against its ongoing appetite for acquisitions

Boston Scientific Corporation: Key facts and statistics - LTM March 20...

A summary company profile, detailing Boston Scientific Corporation’s business operations and financial highlights.

Boston Scientific Corporation: Update to credit analysis following rat...

Our credit view of this issuer reflects its leading position in key markets and its broad product and geographic diversification, against its persistent appetite for acquisitions.

Boston Scientific Corporation: Update to credit analysis

Our credit view of this issuer reflects its significant scale, geographic diversification and strong organic growth track record in medical devices, tempered by its appetite for M&A

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2022 03 15

Ichor Holdings, Ltd. (ICHR) is the dominant player in a critical memory chip subindustry, and it is improving profitability coming out of a difficult two-year period for the industry. Uniform Accounting highlights that the market is missing the company's improving fundamentals, creating an opportunity for equity upside. Ichor is the biggest and highest quality fluid and gas delivery system manufacturer, a key supplier to the growing memory chip market. Difficult supply dynamics in the memory ma...

Valens Research
  • Valens Research

BSX - Embedded Expectations Analysis - 2022 03 08

Boston Scientific (BSX) currently trades near corporate but below historical averages relative to Uniform earnings, with a 25.5x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to remain stable at 27% levels, accompanied by 5% Uniform asset growth. Meanwhile, analysts expect Uniform ROA to improve to 29% in 2023, accompanied by 3% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $44, representing a...

Boston Scientific Corporation: Update to credit analysis following upg...

Our credit view of this issuer reflects its leading position in key markets, clearly articulated leverage target though offset by lingering impacts of COVID-19

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch